Long acting GLP-1 receptor agonist (injectable)
Polyethylene glycol loxenatide 0.2 mg subcutaneous once weekly
PEGLOX_SC_0p2MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.98 (-1.61 to -0.35) | 0.58 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.10 (0.00 to 2.63) | 0.70 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.95 (-9.99 to -1.85) | 0.88 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.00 (0.06 to 13.01) | 0.49 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.64 (0.08 to 4.91) | 0.72 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.98 (0.74 to 176) | 0.24 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.77 (0.10 to 90.81) | 0.47 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.80 (0.19 to 20.85) | 0.46 |